moa of semaglutide How Works: The Science Behind Weight Loss Semaglutide (Ozempic, Wegovy, Rybelsus) -

Current Research Status and Future Directions Where We Are Now (2026) Retatrutide is currently in Phase 3 clinical development under Eli Lilly's TRIUMPH program, which includes multiple trials: TRIUMPH-3 Obesity without type 2 diabetes Evaluating 12mg vs 9mg vs placebo in adults with BMI 30 or 27 with comorbidities TRIUMPH-4 Obesity with type 2 diabetes Testing efficacy and safety in patients with both conditions (preliminary: 28.7% weight loss) MASLD/NASH Trials Metabolic dysfunction-associated steatotic liver disease Leveraging glucagon's liver fat reduction effects Cardiovascular Outcomes Long-term CV safety and benefits Following precedent of STEP and SURMOUNT trials for GLP-1 drugs Timeline to FDA Approval 2023: Phase 2 results published (NEJM) 2024-2026: Phase 3 trials ongoing (TRIUMPH program) 2026-2027: Anticipated FDA submission (if trials successful) 2027-2028: Potential FDA approval and commercial launch What Researchers Are Watching The main questions Phase 3 needs to answer: Long-term efficacy: Does weight loss plateau or continue beyond 48 weeks

'Novo Nordisk (Ozempic, Wegovy, Victoza, Saxenda)', 'Eli Lilly (Mounjaro - Tirzepatide - competitor)', 'AstraZeneca', 'Sanofi SA', 'GlaxoSmithKline', 'Pfizer Inc.', 'Boehringer Ingelheim', 'Merck & Co.', 'Biocon Biologics', 'Teva Pharmaceutical', 'Sun Pharmaceutical', 'Dr

Looking for a Lower-Cost Compounded Option

While Wegovys revenue trailed sharply, volumes jumped 70% to 45,000 units in November following an almost 40% price cut

There was no significant difference between treatment groups in the improvement of liver fibrosis